Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals

Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation

Fineline Cube Oct 10, 2023

Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million...

Company Drug

Atom Bioscience Initiates Global Phase III Clinical Study for Gout Drug ABP-671

Fineline Cube Oct 10, 2023

China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced the enrollment of...

Policy / Regulatory

China’s National Health Commission Launches Three-Year Patient Safety Campaign

Fineline Cube Oct 10, 2023

The National Health Commission has issued a notification to launch a special patient safety campaign...

Company Drug

GluBio Pharmaceutical’s GLB-002 Receives NMPA Approval for Clinical Trials in Hematological Tumors

Fineline Cube Oct 10, 2023

GluBio Pharmaceutical Co., Ltd, a specialist in molecular glue targeted protein degradation (TPD) based in...

Company Medical Device

Med Vision’s Sleep Disorder Software Receives Category II Approval in China

Fineline Cube Oct 10, 2023

Hangzhou-based Med Vision, a provider of virtual reality (VR)-enabled digital therapeutics (DTx) solutions, has reportedly...

Company Drug

Luye Pharma Files NDA for Paliperidone Palmitate Injectable Suspension with US FDA

Fineline Cube Oct 10, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the submission of a New Drug Application...

Company

Apeloa Pharmaceutical Expands Global Footprint with Apeloa Europe GmbH in Germany

Fineline Cube Oct 10, 2023

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

AbbVie Acquires Mitokinin, Advancing PINK1 Activator for Parkinson’s Disease

Fineline Cube Oct 10, 2023

AbbVie (NYSE: ABBV) has announced the acquisition of US-based biotechnology company Mitokinin, exercising an exclusive...

Company Drug

Shanghai BDgene’s BD112 Earns Orphan Drug Designation from US FDA for Huntington’s Disease

Fineline Cube Oct 10, 2023

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has announced that its drug...

Company

AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit

Fineline Cube Oct 10, 2023

Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...

Company Deals

AffaMed Technologies Secures Exclusive Rights to SIFI’s Intraocular Lens Products in Greater China

Fineline Cube Oct 10, 2023

AffaMed Technologies, a joint venture between China’s AffaMed Therapeutics and Italy-based SIFI S.p.A., has announced...

Company Deals

Simcere Pharmaceutical Secures Exclusive Rights to AnDiCon’s Anti-Influenza Candidate ADC189

Fineline Cube Oct 10, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced a strategic collaboration agreement with domestic firm...

Company Drug

J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial

Fineline Cube Oct 10, 2023

Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...

Company Deals

BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal

Fineline Cube Oct 10, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...

Company Deals

Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology

Fineline Cube Oct 9, 2023

The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen...

Company Deals

Adlai Nortye Completes Successful IPO on Nasdaq, Raising $57.5 Million

Fineline Cube Oct 9, 2023

Sino-US biotech Adlai Nortye Ltd (NASDAQ: ANL) successfully completed its initial public offering (IPO) on...

Company Drug

Eli Lilly Launches Three New Oncology Programs Targeting KRAS and Nectin-4

Fineline Cube Oct 9, 2023

Eli Lilly (NYSE: LLY) has announced the initiation of three innovative oncology programs focusing on...

Company Drug

FDA Rejects Eli Lilly’s Application for Lebrikizumab in Atopic Dermatitis Treatment

Fineline Cube Oct 9, 2023

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s (NYSE: LLY) application for...

Company Deals

Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas

Fineline Cube Oct 9, 2023

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...

Policy / Regulatory

Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030

Fineline Cube Oct 9, 2023

The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...

Posts pagination

1 … 410 411 412 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.